| A Trial to Evaluate the Effect of Esomeprazole on the Pharmacokinetics of Emraclidine in Healthy Adult Participants (NCT06366243) | Cerevel Therapeutics, LLC | 2024-05-10 |
| A Study to Assess Mass Balance, Pharmacokinetics, Metabolism, and Excretion of Emraclidine in Healthy Adult Male Participants (NCT06301971) | Cerevel Therapeutics, LLC | 2024-03-04 |
| A Trial to Evaluate the Effects of Itraconazole and Carbamazepine on the Pharmacokinetics of Emraclidine and of Emraclidine on the Pharmacokinetics of Metformin in Healthy Adult Participants (NCT05965219) | Cerevel Therapeutics, LLC | 2023-08-15 |
| A Study Evaluating the Pharmacokinetics and Relative Bioavailability of Emraclidine Immediate-Release Tablets in Healthy Adult Participants (NCT05933187) | Cerevel Therapeutics, LLC | 2023-07-19 |
| The Effect of Food on the Pharmacokinetics (PK) of Emraclidine in Healthy Adult Participants (NCT05915546) | Cerevel Therapeutics, LLC | 2023-06-08 |
| Open-label Trial to Evaluate the Effect Carbamazepine on Darigabat Pharmacokinetics in Healthy Adult Participants (NCT05824143) | Cerevel Therapeutics, LLC | 2023-04-17 |
| Positron Emission Tomography (PET) Trial to Evaluate Target Occupancy of CVL-354 at Kappa and Mu Opioid Receptors in Brain Following Oral Dosing (NCT05547542) | Cerevel Therapeutics, LLC | 2023-03-02 |
| Multiple-dose Trial to Determine the Clinical Bioequivalence Between Tavapadon Tablets in Participants With Parkinson's Disease (NCT05610189) | Cerevel Therapeutics, LLC | 2022-12-15 |
| Study to Evaluate the Effects of Cytochrome P450 (CYP) 3A4 Inducer Carbamazepine on Tavapadon Pharmacokinetics in Healthy Adult Participants (NCT05581823) | Cerevel Therapeutics, LLC | 2022-10-19 |
| To Evaluate Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Severe Renal Impairment Compared to Participants With Normal Renal Function (NCT05404542) | Cerevel Therapeutics, LLC | 2022-05-10 |
| To Evaluate the Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Mild and Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function (NCT05404529) | Cerevel Therapeutics, LLC | 2022-04-29 |
| Trial to Study the Effect of CVL-231 on 24-Hour Ambulatory Blood Pressure in Participants With Schizophrenia (NCT05245539) | Cerevel Therapeutics, LLC | 2022-01-24 |
| Relative Bioavailability and Food Effect Following Single Oral Dose of Darigabat Tablet Formulations in Healthy Participants (NCT05123079) | Cerevel Therapeutics, LLC | 2021-11-02 |
| A Single and Multiple Ascending Dose Trial of CVL-354 in Healthy Participants (NCT05138653) | Cerevel Therapeutics, LLC | 2021-10-18 |
| PET Trial to Evaluate Target Occupancy of CVL-231 on Brain Receptors Following Oral Dosing (NCT04787302) | Cerevel Therapeutics, LLC | 2021-06-01 |
| A Trial of the Effect of CVL-865 on Panic Symptoms Induced by Carbon Dioxide Inhalation in Healthy Subjects (NCT04592536) | Cerevel Therapeutics, LLC | 2020-10-06 |
| An Open-label Trial to Evaluate Mass Balance of Tavapadon at Steady State in Healthy Subjects (NCT04241393) | Cerevel Therapeutics, LLC | 2020-02-04 |
| A 2-Part Trial of CVL-751 in Subjects With Parkinson's Disease (NCT04295642) | Cerevel Therapeutics, LLC | 2020-01-08 |
| A Multiple Ascending Dose Trial of CVL-231 in Subjects With Schizophrenia (NCT04136873) | Cerevel Therapeutics, LLC | 2019-10-15 |